Johnson & Johnson Stock News

With continued volatility in the stock market right now, it's no wonder investors are looking for stocks with proven track records to bolster their portfolios. While U.S. stocks opened strong on Monda

The World Health Organization is likely to issue a wider warning about contaminated Johnson and Johnson-made children's cough syrup found in Nigeria last week, it said in an email.

Johnson & Johnson (NYSE: JNJ) recently reported its Q1 results, with revenues marginally below but earnings exceeding our estimates. The company reported revenue of $21.4 billion and adjusted earnings

A Florida jury on Thursday concluded that Johnson & Johnson's baby powder talc product did not cause the ovarian cancer of a Florida woman who died in 2019.

Finding reliable assets is crucial in the current unstable environment. Even amid economic uncertainty, certain equities hold their value and offer steady returns.

Tax refunds are landing in bank accounts and mailboxes across America, giving people some extra money to play with. As of the federal income tax deadline of April 15, the Internal Revenue Service (IRS

Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.

The healthcare titan unveiled its first set of quarterly results for 2024. It missed slightly on the top line but beat on profitability.

The Investment Committee discuss some big movers in the market today.

Johnson & Johnson (J&J) has emphasized the pivotal role of medical technology (MedTech) in advancing healthcare. During a Tuesday (April 16) call with analysts to discuss the first quarter (Q1) and f

CFRA views the newly announced $13.1B Johnson & Johnson (JNJ) shockwave deal as positive. David Toung and Sel Hardy discuss the takeaways from Johnson & Johnson's earnings.

Building Permits Come in Lower Than Expected.

J&J (JNJ) beats estimates for first-quarter earnings but misses the same for sales. It tightens its sales and earnings growth expectations for 2024.

Both Housing Starts and Building Permits missed expectations, while BofA, J&J and UnitedHealth all beat on earnings.

Johnson & Johnson (NYSE:JNJ) reported better-than-expected first quarter profits driven by strong sales of its cancer drugs, but shares of the pharma giant traded lower as revenue narrowly missed esti